FULGENT GENETICS, INC.

Fulgent Genetics, Inc. specializes in advanced genetic testing services for clinical and research applications, delivering precision diagnostics through next-generation sequencing and molecular analysis platforms. Their core capabilities center on the interpretation of genomic data to support personalized medical decision-making, particularly in oncology, rare disease identification, and inherited condition screening. The company employs validated laboratory workflows compliant with CLIA and CAP standards, integrating bioinformatics pipelines to transform raw sequencing data into clinically actionable reports. Their technical expertise includes variant classification, copy number analysis, and germline/somatic mutation detection, with a focus on high-complexity diagnostic assays used in patient care settings. Differentiators include rapid turnaround times, scalable testing capacity, and seamless integration with electronic health record systems to support clinical workflows. Fulgent Genetics has demonstrated direct engagement with the Department of Veterans Affairs, providing genetic testing services tailored to the VA Portland Health Care System’s veteran population. This relationship reflects a focused partnership in delivering specialized genomic diagnostics to support veteran-specific health needs, including hereditary cancer risk assessment and pharmacogenomic applications. The contractor operates primarily under NAICS 621511, which encompasses medical laboratories performing diagnostic testing, positioning them within the clinical diagnostics sector serving federal healthcare providers. Their market focus is narrow but deep, targeting high-acuity genetic testing applications rather than broad-based clinical lab services. Fulgent Genetics, Inc. is a small business structured as a 2L entity, headquartered in El Monte, California. While no federal certifications are currently listed, the company maintains operational compliance with clinical laboratory quality standards essential for federal contracting. Their geographic presence is centered in Southern California, with service delivery oriented toward federal healthcare networks requiring advanced molecular diagnostics.